Novel Therapeutics


The commonly used drug to treat Parkinson’s disease is Levodopa which has higher frequency to develop motor Fluctuations and results in L-dopa-induced dyskinesia (LID). Since the Characteristic key cause of Parkinson’s disease is reduced production level dopamine by neurons, research studies developed a molecule called LXR (Liver X Receptor) where it has got potential to reduce the loss of dopaminergic neurons. Researchers propose novel ideas to treat Parkinson’s disease to reduce the risk of causing side effects, frequency of dyskinesia, to treat cognitive disorders such as anxiety and depression.



 


  • Repetitive Transcranial Magnetic Stimulation
  • NMDA Receptor for Cognitive Dysfunction

Related Conference of Novel Therapeutics

July 20-21, 2026

37th World Congress on Neurology and Neuroscience

Amsterdam, Netherlands
July 23-24, 2026

14th International Conference on Cannabis & Medicinal Research

Amsterdam, Netherlands
September 18-19, 2026

21st Annual Congress on Neuroscience

Dubai, UAE
November 16-17, 2026

8th World Brain Congress

Tokyo, Japan
November 23-24, 2026

16th Global Alzheimers Summit

Paris, France
November 24-25, 2026

38th World Conference on Neurology

Rome, Italy
December 21-22, 2026

6th International Conference on Child Neurology

Paris, France
December 28-29, 2026

39th European Neurology Congress

Amsterdam, Netherlands
December 28-29, 2026

18th Global Neurologists Meeting on Neurology and Neurosurgery

Amsterdam, Netherlands
March 22-23, 2027

8th International Conference on Neurologists

Singapore City, Singapore

Novel Therapeutics Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in